2. UroToday Home
  3. UroToday

Bladder Cancer

Pathological Assessment of Morcellated Tissue after ERBT: Insights from a Two-Round Delphi Survey - Beyond the Abstract

Details
En bloc resection of bladder tumor (ERBT) is becoming increasingly popular because of several potential advantages over conventional trans urethral resection of bladder tumor (TURBT). Multiple studies have demonstrated better specimen quality, higher detrusor muscle detection rates, improved surgical margins, fewer bladder perforations, and lower catheterization time.1–5 Modern laser systems further facilitated the development of ERBT by allowing more controlled dissection with minimal bleeding and limited thermal damage to the specimen.6–8

EAU Guidelines on Nonmuscle-invasive Bladder Cancer (TaT1 and CIS) - A Summary of the 2026 Guidelines Update.

Details

This publication represents a summary of the updated 2026 European Association of Urology (EAU) Guidelines for nonmuscle-invasive bladder cancer (NMIBC), TaT1 and carcinoma in situ (CIS). The information presented herein is limited to urothelial carcinoma, unless specified otherwise.

Novel BCG Combination or Modified BCG Regimens in BCG-Naïve High-risk Non-muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis.

Details

Despite Bacillus Calmette-Guerin (BCG) remaining the standard of care for high-risk non-muscle-invasive bladder cancer (HR-NMIBC), novel combination strategies are being actively investigated. Comparative evidence on the efficacy and tolerability of these regimens in BCG-naïve patients remains limited.

Robot-Assisted Radical Cystectomy: Recommendations from Latin American Experts Consensus on Surgical Strategy, Urinary Reconstruction, and Oncological and Func-tional Outcomes.

Details

To develop contemporary evidence-informed recommendations for robot-assisted radical cystectomy (RARC), urinary reconstruction, and perioperative management, integrating current evidence with the experience of Latin American experts in uro-oncology and robotic surgery.

Oncogenic PIK3CA reprograms glutamine metabolism to drive bladder cancer progression.

Details

Genomic analysis has revealed that approximately 40% of bladder cancer (BLCA) tumors harbor alterations in the PI3K/AKT pathway, with PIK3CA mutations occurring in 15-25% of cases. PIK3CA, which encodes the catalytic p110α subunit of PI3K, plays a critical role in regulating cell survival, proliferation, and metabolism.

Integrating the Neutrophil-to-Lymphocyte Ratio into a Clinicopathological Nomogram for Event-Free Survival Prediction in Cisplatin-Treated Muscle-Invasive Bladder Cancer.

Details

Neoadjuvant cisplatin-based chemotherapy (NAC) followed by radical cystectomy (RC) is a standard treatment for cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC), yet baseline tools to refine prognostic stratification remain limited.

Substaging and Stratified Treatment of T1 Bladder Cancer - a Nationwide Register-Based Study.

Details

Substaging of T1 bladder cancer (BC) was implemented in Denmark in 2010 based on depth of lamina propria invasion-pT1a (superficial) and pT1b (deep)-with bladder-sparing therapy recommended for pT1a and early cystectomy for pT1b.

Artificial intelligence and predictive tools in non-muscle invasive bladder cancer: a narrative review of current insights and advances.

Details

Non-muscle invasive bladder cancer (NMIBC) is characterized by high recurrence rates and heterogeneous progression risk, making accurate diagnosis, risk stratification, and personalized management challenging.

Time to Treatment Initiation and Survival in Patients With Muscle-Invasive Bladder Cancer (MIBC) - Beyond the Abstract

Details
The optimal management of muscle-invasive bladder cancer (MIBC) depends not only on selecting the appropriate therapeutic strategy but also on minimizing the time from diagnosis to the initiation of the first curative-intent treatment.

Factors Influencing Adherence to Intravesical Instillation Therapies for Non-Muscle-Invasive Bladder Cancer: A Scoping Review Protocol - Beyond the Abstract

Details
Intravesical therapy remains a cornerstone in the management of non–muscle-invasive bladder cancer (NMIBC), with Bacillus Calmette-Guérin (BCG) representing the standard of care for patients with intermediate- and high-risk disease. Despite its established efficacy, treatment is associated with a substantial patient burden related to frequent outpatient visits and a broad spectrum of local and systemic side effects. Common toxicities include lower urinary tract symptoms such as urinary frequency, urgency, dysuria, and bladder irritation, as well as fatigue, hematuria, fever, and flu-like symptoms.1

AI-MIRACLE: Artificial Intelligence and MultIpaRAmetric MRI Predict CLinical OutcomEs to Neoadjuvant Immunotherapy in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy - Beyond the Abstract

Details
Multiparametric MRI has been increasingly proposed as a tool to assess response after neoadjuvant therapy in muscle-invasive bladder cancer (MIBC), particularly in the context of emerging bladder-sparing strategies. However, its clinical implementation remains challenging. Accurate interpretation requires dedicated and trained radiologists; interreader variability persists even with standardized scoring systems, and MRI performance is still suboptimal when the target is the identification of pathological complete response. These limitations support the development of automated and accurate AI tools that may assist clinicians in evaluating response after treatment.

Effectiveness and safety of enfortumab vedotin and pembrolizumab in a real-world patient population with urothelial carcinoma: results from a multi-institutional cohort (GUARDIANS).

Details

Enfortumab vedotin plus pembrolizumab (EVP) is the standard first-line treatment for metastatic or locally advanced urothelial carcinoma (m/laUC). Real-world patients frequently present with unfavorable clinical characteristics, raising uncertainty about whether outcomes mirror those of the pivotal EV-302/KEYNOTE-A39 trial.

Immunohistochemistry-Based Molecular Subtyping in Muscle-Invasive Bladder Cancer: Predicting Response to Neoadjuvant Chemotherapy.

Details

Muscle-invasive bladder cancer (MIBC) presents a heterogeneous response to perioperative chemotherapy. Although several molecular classifications of MIBC have been proposed, two main subtypes, namely, luminal and basal, are widely recognised.

Assessing the concordance between ChatGPT-4 and EAU guidelines indications in bladder cancer management: a real-world study.

Details

The integration of Artificial Intelligence (AI), particularly Large Language Models (LLMs) like ChatGPT, into healthcare is reshaping patient information-seeking behaviors. While prior studies have evaluated ChatGPT's performance across various urological domains, no research has yet addressed its ability to provide guideline-concordant recommendations for Bladder Cancer (BCa) management based on histopathological findings.

Proteomic analysis of sphingolipid metabolic enzymes with risk of bladder cancer incidence and mortality in the Atherosclerosis Risk in Communities (ARIC) Study.

Details

Lipid metabolism is regarded as a hallmark of cancer. Sphingolipids, a family of structural and signaling lipids, have antiproliferative (ceramides) or pro-survival (sphingosine 1 phosphate [S1P]) function.

Comparative effectiveness of intravesical gemcitabine vs. sequential gemcitabine and docetaxel for high-risk nonmuscle-invasive bladder cancer.

Details

Sequential intravesical gemcitabine and docetaxel (Gem/Doce) are increasingly used for nonmuscle-invasive bladder cancer (NMIBC), especially in the setting of Bacillus Calmette-Guérin (BCG) shortage or failure.

U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

Details
  • First and only treatment regimen for adults with MIBC, regardless of cisplatin eligibility, representing a platinum-free potential standard of care
  • Broadened approval supported by Phase 3 EV-304 data showing a nearly 50% reduction in the risk of tumor recurrence, progression or death, and a 35% reduction in the risk of death, versus standard of care in cisplatin-eligible patients
Las Vegas, Nevada (UroToday.com) -- Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV® (enfortumab vedotin-ejfv), a Nectin-4 directed antibody-drug conjugate, plus the PD-1 inhibitor, Keytruda® (pembrolizumab) or Keytruda QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) as neoadjuvant and adjuvant (before and after surgery) treatment for adult patients with muscle-invasive bladder cancer regardless of cisplatin eligibilityi. This now marks the first platinum-free regimen approved for adult patients with MIBC, regardless of cisplatin eligibility.

MRI-based Response Assessment of Neoadjuvant Systemic Immunotherapy in Muscle-invasive Bladder Cancer: An Analysis of Inter-radiologist Variability and Diagnostic Accuracy in three Prospective Clinical Trials.

Details

For patients with muscle-invasive bladder cancer (MIBC), accurate assessment of neoadjuvant therapy response may allow for bladder-sparing strategies, emphasizing the need for accurate, noninvasive response assessment.

Molecular Profiling of Urothelial Bladder Cancer: Bridging Tumor Biology and Clinical Decision-making.

Details

Bladder cancer ranks among the most common malignancies worldwide, with urothelial carcinoma as the predominant histological type. Its development from normal urothelium to non-muscle-invasive bladder cancer (NMIBC) or muscle-invasive bladder cancer (MIBC) is driven by complex molecular events, including chromosomal aberrations, somatic mutations, and epigenetic dysregulation.

Impact of body mass index on outcomes after radical cystectomy: A retrospective Australian cohort study.

Details

This study aimed to assess the association between body mass index and perioperative outcomes and survival after radical cystectomy for bladder cancer in an Australian cohort.

We conducted a retrospective single-centre study of patients undergoing radical cystectomy between 2008 and 2021.